I had somewhat of a fear that patients with MS really didn't like change as long as the meds were containing their disease. I'm very surprised that Teva has been able to switch so many patients to the 3X delivery schedule because that means patients won't have much concern going over to a generic if there is one.
Now that the generic has slipped into Jan and then Feb I'm starting too think that what the FDA really meant when it last responded to Teva's CP was that the CP had no merit because the FDA wasn't even close to approving anything.
Market Data 
Markets 
AI
